Generate Biomedicines Enters into a Collaboration with Roswell Park Comprehensive Cancer Center to Advance the Development Novel Cell Therapies for Oncology Using Generative AI

Published: November 2023


On 01 November 2023, Generate Biomedicines entered into a strategic collaboration with Roswell Park Comprehensive Cancer Center to discover and develop chimeric antigen receptor T-cell therapies (CAR T cell therapies) for oncological disorders, including ovarian cancer and other solid tumors, using generative AI. The collaboration aims to combine the scalability and programmability of The Generate Platform and Roswell Park’s expertise in cell therapy design, clinical development, and manufacturing. 

As per the terms of agreement, Generate Biomedicines and Roswell Park Comprehensive Cancer Center are expected to share research and development expenses as well as profits generated through commercialization of products that emerge from the collaboration. It is anticipated that Roswell Park will serve as a site and recommend lead investigators for Phase I and II clinical trials.

According to Roots Analysis, the AI in Oncology Market is estimated to be worth $1.1 billion in 2023 and is expected to grow at a remarkable CAGR of 54% during the forecast period.
 
For detailed insights about this domain, check out our report on AI in Oncology Market or email sales@rootsanalysis.com

You may also be interested in the following titles: 

  1. CAR T Cell Therapy Market (4th Edition), 2022-2035
  2. Allogeneic Cell Therapy Market, 2023-2035
  3. TCR Therapy Market, 2022-2035

MEDIA CITATIONS

  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry